|
Genedrive PLC - Manchester, England-based point-of-care pharmacogenetic testing company - Notes the presentation of two posters by authors from the NHS England Network of Excellence in Pharmacogenomics, the NHSE Genomics Unit, the NHSE National Stroke Programme, and the Manchester Centre for Genomic Medicine at the UK Stroke Forum in Aberdeen, Scotland. Says results included laboratory CYP2C19 testing and point-of-care rapid CYP2C19 genetic testing using the Genedrive CYP2C19 ID kit. Key findings included that ‘a higher prevalence of patients unlikely to respond to clopidogrel [was] identified in the near-patient arm’, leading Genedrive to estimate that an additional roughly 4,200 per year stroke patients benefitting from alternative prescribing decisions could be identified using the CYP2C19 ID kit ‘due to its increased target coverage and ethnic inclusivity’. Posters add: ‘Test results impacted prescription practices, guiding prescription changes and aligning treatment with patients’ genetic profiles for better outcomes.’ Additionally: ‘Implementation of Genedrive CYP2C19 testing was feasible, scalable and effective in providing immediate availability of results during acute clinical settings. Moreover, the findings substantiate the clinical utility of CYP2C19 genotype-guided antiplatelet therapy in the management of patients with ischemic stroke or TIA, particularly with diverse British and European populations.’ Chief Executive Officer Gino Miele comments: ‘We are pleased to report the presentation of the data underpinning the NHS CYP2C19 testing implementation guidelines, clearly highlighting the positive case for implementation of our rapid CYP2C19 testing platform...We look forward to progressing with integrated care boards and the dynamic procurement system team to deliver our cost-saving, life-changing transformational solution to stroke patients nationally.’ Current stock price: 1.02 pence 12-month change: down 44% Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
